AHRR (cg05575921) Methylation Safely Improves Specificity of Lung Cancer Screening Eligibility Criteria: A Cohort Study.

Katja Kemp JacobsenPeter SchnohrGorm Boje JensenStig Egil Bojesen

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2022)

The results point toward a potential clinical use of AHRR (cg05575921) methylation, which is a cost-effective measurement compared with lung CT scanning, to provide additional predictive risk information to identify eligible smokers for lung cancer screening. See related commentary by Hung, p. 698.

Keyphrases

dna methylation
genome wide
computed tomography
smoking cessation
image quality
healthcare
magnetic resonance imaging
magnetic resonance
dual energy
risk assessment
human health
mass spectrometry